REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental antibody takes aim at tough lymphoma
Disease control OngoingThis early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …
Matched conditions: REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to tackle tough lymphoma
Disease control TerminatedThis phase 2 trial tests the safety and effectiveness of combining two drugs, epcoritamab and tazemetostat, for patients with follicular lymphoma that has relapsed or is refractory. The study plans to enroll 33 adults. Epcoritamab helps the immune system attack cancer cells, whil…
Matched conditions: REFRACTORY GRADE 3A FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC